Patent intelligence · US
US 6207170
Patient-specific white blood cell malignancy vaccine from membrane-proteoliposomes
Patient-specific white blood cell malignancy vaccine from membrane-proteoliposomes
Patent details — US 6207170
- Jurisdiction
- US
- Status
- expired
- Grant date
- Mar 27, 2001
- Expiration
- Mar 22, 2021
- Applicant
- Biomira USA Inc.
- Claims
- 21
- CPC classes
- A61K, A61K2039/55522, A61K2039/55527, A61K2039/55533
Quick answer
US 6207170 (Patient-specific white blood cell malignancy vaccine from membrane-proteoliposomes) is held by Biomira USA Inc.. Status: expired. Granted Mar 27, 2001. Expires Mar 22, 2021 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Biomira USA Inc.
- Grant date
- Expiration
- Claims
- 21
- CPC classes
- A61K, A61K2039/55522, A61K2039/55527, A61K2039/55533, A61K2039/5555, A61K2039/55572
More from Biomira USA Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12421228
Naphthyridine derivatives as PRC2 inhibitors
granted -
US 12421253
Tetrahydropyridopyrimidine pan-KRas inhibitors
granted -
US 12414911
Topical compositions and methods of use
granted -
US 12412764
Substrate-accommodating container
granted -
US 12398154
Azaquinazoline pan-KRas inhibitors
granted -
US 12383503
Adagrasib solid pharmaceutical compositions
granted -
US 12377101
Combination therapies
granted -
US 12371435
Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors
granted
Frequently asked questions
What is US patent 6207170?
US 6207170 (Patient-specific white blood cell malignancy vaccine from membrane-proteoliposomes) is held by Biomira USA Inc.. Status: expired. Granted Mar 27, 2001. Expires Mar 22, 2021 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 6207170?
Biomira USA Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 308 pharmaceutical patents for this assignee.
When does US 6207170 expire?
Our index shows an expiration date of Mar 22, 2021 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.